SGLT-2 inhibitor + metformin

1. SGLT-2 inhibitor + metformin is associated with renal and urinary disorders in humans (ROR = 3.91).

   Humanspharmacovigilance disproportionality analysis

   Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database · Frontiers in endocrinology · 4 Sep 2026

Renal and urinary disorders →

1. SGLT-2 inhibitor + metformin is associated with metabolism and nutrition disorders in humans (ROR = 9.00).

   Humanspharmacovigilance disproportionality analysis

   Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database · Frontiers in endocrinology · 4 Sep 2026

Metabolism and nutrition disorders →

1. SGLT-2 inhibitor + metformin is associated with euglycaemic diabetic ketoacidosis in humans (ROR = 335.43).

   Humanspharmacovigilance disproportionality analysis relative to other reports

   Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database · Frontiers in endocrinology · 4 Sep 2026

Euglycaemic diabetic ketoacidosis →